Beijing SL Pharmaceutical Co., Ltd. (002038.SZ)
CNY 7.26
(0.41%)
CNY 7.26
(0.41%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 1.01 Billion | 1.05 Billion | 1.21 Billion | 1.11 Billion | 2.02 Billion | 2.16 Billion |
| Cost of Revenue | 305.5 Million | 156.95 Million | 183.57 Million | 163.42 Million | 417.37 Million | 448.27 Million |
| Gross Profit | 712.85 Million | 893.2 Million | 1.03 Billion | 949.31 Million | 1.61 Billion | 1.71 Billion |
| Operating Expenses | 491.63 Million | 711.19 Million | 776.09 Million | 779.9 Million | 1.1 Billion | 1.05 Billion |
| Selling, General and Administrative Expenses | 326.7 Million | 450.29 Million | 497.21 Million | 515.69 Million | 913.79 Million | 922.27 Million |
| Research and Development Expenses | 177.1 Million | 161.64 Million | 196.14 Million | 188.64 Million | 128.35 Million | 72.89 Million |
| Other Expenses | -1.02 Million | 99.24 Million | 82.72 Million | 75.57 Million | 66.4 Million | -9.99 Million |
| Cost and Expenses | 540.48 Million | 868.15 Million | 959.66 Million | 943.33 Million | 1.52 Billion | 1.49 Billion |
| Operating Income | 477.86 Million | 263.31 Million | 457.54 Million | 412.88 Million | 560.9 Million | 681.63 Million |
| Interest Expense | 66.11 Thousand | 102.56 Thousand | 225.29 Thousand | 354.12 Thousand | 94 Thousand | 20.82 Million |
| Income Tax Expense | 49.93 Million | 31 Million | 36.51 Million | 51.32 Million | 81.38 Million | 108.25 Million |
| Earnings before Tax | 464.89 Million | 259.35 Million | 457.83 Million | 412.77 Million | 560.88 Million | 671.64 Million |
| Net Income | 416.69 Million | 234.4 Million | 425.93 Million | 364.7 Million | 486.78 Million | 571.44 Million |
| Earnings Per Share Basic | 0.41 | 0.23 | 0.41 | 0.36 | 0.47 | 0.83 |
| Earnings Per Share Diluted | 0.41 | 0.23 | 0.41 | 0.36 | 0.47 | 0.83 |
| Weighted Average Shares Outstanding | 1.01 Billion | 1.02 Billion | 1.02 Billion | 1.02 Billion | 1.03 Billion | 684.86 Million |
| Weighted Average Shares Outstanding (Diluted) | 1.01 Billion | 1.02 Billion | 1.02 Billion | 1.02 Billion | 1.03 Billion | 684.86 Million |
| Gross Margin | 0.70 | 0.85 | 0.85 | 0.85 | 0.79 | 0.79 |
| EBIT Margin | 0.60 | 0.40 | 0.49 | 0.43 | 0.32 | 0.35 |
| Profit Margin | 0.41 | 0.22 | 0.35 | 0.33 | 0.24 | 0.26 |
| EBITDA | 610.29 Million | 363.78 Million | 539.84 Million | 492.84 Million | 644.61 Million | 735.51 Million |
| Earnings Before Tax Margin | 0.47 | 0.25 | 0.38 | 0.37 | 0.28 | 0.31 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 148.49 Million | 144.41 Million | 243.51 Million | 1 Billion | 238.63 Million | 193.12 Million |
| Cost of Revenue | 80.9 Million | 62.59 Million | 58 Million | 305.5 Million | 70.81 Million | 54.17 Million |
| Gross Profit | 67.59 Million | 81.81 Million | 185.5 Million | 702.76 Million | 167.82 Million | 138.94 Million |
| Operating Expenses | 120.58 Million | 70.83 Million | 83.93 Million | 491.63 Million | 143.85 Million | 143.56 Million |
| Selling, General and Administrative Expenses | 146.44 Million | 44.13 Million | 55.87 Million | - | 70.97 Million | 157.98 Million |
| Research and Development Expenses | 41.51 Million | 26.7 Million | 28.05 Million | - | 71.86 Million | 40.1 Million |
| Other Expenses | -67.37 Million | -4444.20 | 1500.01 | -1.02 Million | -1.02 Million | -113.63 Million |
| Cost and Expenses | 201.49 Million | 133.43 Million | 141.94 Million | 797.13 Million | 214.66 Million | 197.74 Million |
| Operating Income | -50.8 Million | 10.98 Million | 101.57 Million | 211.13 Million | 23.96 Million | -5.74 Million |
| Interest Expense | - | - | - | 66.11 Thousand | - | - |
| Income Tax Expense | -9.11 Million | -11.78 Million | 1.48 Million | 49.93 Million | 21.52 Million | -5.78 Million |
| Earnings before Tax | -55.64 Million | -52.67 Million | 71.15 Million | 452.62 Million | 107.99 Million | -5.73 Million |
| Net Income | -46.32 Million | -40.54 Million | 70.13 Million | 416.69 Million | 99.12 Million | 403.95 Thousand |
| Earnings Per Share Basic | -0.05 | -0.04 | 0.07 | - | 0.10 | 0.00 |
| Earnings Per Share Diluted | -0.05 | -0.04 | 0.07 | - | 0.10 | 0.00 |
| Weighted Average Shares Outstanding | 1.02 Billion | 1.02 Billion | 1.02 Billion | 1.02 Billion | 1.02 Billion | 1.02 Billion |
| Weighted Average Shares Outstanding (Diluted) | 1.02 Billion | 1.02 Billion | 1.02 Billion | 1.02 Billion | 1.02 Billion | 1.02 Billion |
| Gross Margin | 0.46 | 0.57 | 0.76 | 0.70 | 0.70 | 0.72 |
| EBIT Margin | -0.36 | 0.33 | 0.65 | - | 0.27 | -1.15 |
| Profit Margin | -0.31 | -0.28 | 0.29 | 0.41 | 0.42 | 0.00 |
| EBITDA | -52.99 Million | 47.65 Million | 158.77 Million | - | 63.54 Million | -222.73 Million |
| Earnings Before Tax Margin | -0.34 | 0.08 | 0.42 | 0.21 | 0.10 | -0.03 |
BTCY
NEOEN
ASGR
000607
0874
BNB